Candel Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 8.65 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 661.89M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery pl...